VELTASSA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VELTASSA (VELTASSA).
VELTASSA (patiromer) is a non-absorbed polymer that binds potassium ions in the gastrointestinal tract, reducing serum potassium levels by increasing fecal potassium excretion.
| Metabolism | Not metabolized; eliminated unchanged in feces. |
| Excretion | Primarily eliminated via feces as insoluble, non-absorbed polymer (80-90%); minimal renal excretion (<0.01% of administered dose as intact drug in urine), biliary excretion negligible. |
| Half-life | Not applicable due to non-systemic action; patiromer acts locally in the gastrointestinal tract and is not absorbed. Elimination half-life of the polymer is not measurable clinically. |
| Protein binding | Not absorbed, therefore protein binding is not applicable; the drug is not systemically available. |
| Volume of Distribution | Not applicable (non-systemic); Vd cannot be measured as the drug is not absorbed into systemic circulation. |
| Bioavailability | Negligible (<0.01%) after oral administration; patiromer acts locally and is not absorbed due to high molecular weight and non-digestible polymer structure. |
| Onset of Action | Oral: Onset of serum potassium reduction occurs within 4-7 hours after a single dose; clinically important reduction typically seen within 48 hours of initiating therapy. |
| Duration of Action | Duration of effect persists for at least 24 hours after steady state (achieved within 2-3 days); effect wanes within 2-3 days after discontinuation. Continuous daily dosing maintains potassium control. |
| Molecular Weight | High molecular weight polymer (not a single small molecule); approximate average molecular weight >100,000 Da. |
8.4 g (1 packet) orally once daily; titrate to a maximum of 25.2 g (3 packets) once daily as needed to achieve normokalemia.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment is required for mild to moderate renal impairment (eGFR 30-89 mL/min/1.73 m²). For severe renal impairment (eGFR <30 mL/min/1.73 m²) or dialysis-dependent patients, use with caution; starting dose 8.4 g once daily with close monitoring of serum potassium. |
| Liver impairment | No specific dose adjustment recommended for Child-Pugh Class A or B. For Child-Pugh Class C (severe hepatic impairment), use with caution due to lack of data; no dose adjustment proposed. |
| Pediatric use | Safety and efficacy have not been established in pediatric patients (age <18 years). No recommended dosing. |
| Geriatric use | No specific dose adjustment required. Elderly patients may have decreased renal function; monitor serum potassium and renal function periodically. |
| 1st trimester | Animal studies have not been conducted; no human data available. Use only if potential benefit justifies risk. |
| 2nd trimester | No human data; potential for maternal electrolyte disturbances affecting fetus. Use with caution. |
| 3rd trimester | No human data; potential for neonatal hypokalemia or hyperkalemia if maternal electrolyte imbalance occurs. |
Clinical note
Comprehensive clinical and safety monograph for VELTASSA (VELTASSA).
| Placental transfer | Patiromer is a non-absorbed polymer; minimal systemic absorption, so negligible placental transfer expected. |
| Breastfeeding | No human data on excretion in breast milk; consider developmental benefits of breastfeeding against mother's need for drug. Monitor infant for electrolyte disturbances. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to patiromer or any componentSevere hyperkalemia requiring emergency treatment (e.g., >7.0 mEq/L)
| Precautions | Bowel obstruction or perforation risk in patients with gastrointestinal disorders, Severe constipation, Hypomagnesemia, Increased risk of gastrointestinal adverse events when used with certain drugs |
| Food/Dietary | Take with food to improve tolerability. No specific dietary restrictions beyond standard potassium management. Avoid high-potassium foods if directed by physician. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category C. In animal reproduction studies, patiromer administered to pregnant rats and rabbits at doses up to 10 times the human clinical dose (6.3 g/day) showed no evidence of fetal harm. However, no adequate and well-controlled studies in pregnant women. Potential risks: maternal electrolyte disturbances (e.g., hypokalemia, hypomagnesemia) may pose fetal risk; use only if clearly needed. |
| Fetal Monitoring | Monitor serum potassium, magnesium, and electrolytes regularly, especially during pregnancy and postpartum. Assess for signs of hypokalemia or hypomagnesemia (e.g., muscle weakness, arrhythmias). Fetal monitoring per routine prenatal care; no specific fetal monitoring required due to lack of systemic absorption. |
| Fertility Effects | No human studies on fertility. In animal studies, no adverse effects on male or female fertility were observed in rats at doses up to 10 times the human clinical dose. |
| VELTASSA (patiromer) is a non-absorbed potassium-binding polymer used for hyperkalemia. Administer at least 3 hours apart from other oral medications due to binding risk. Monitor serum potassium periodically; reduce dose or discontinue if hypokalemia occurs. Not for emergency treatment of life-threatening hyperkalemia due to slow onset. Avoid in patients with bowel obstruction or severe constipation. |
| Patient Advice | Take exactly as prescribed, usually once daily with food. · Separate from other oral medications by at least 3 hours. · Mix powder with water (approximately 120 mL) and stir; drink immediately. · Do not heat or add to hot foods/liquids. · Contact doctor if experiencing constipation, severe stomach pain, or signs of low potassium (muscle cramps, weakness, irregular heartbeat). · Keep medication at room temperature; do not freeze. |